ResMed enters amended $1.5B revolver and $200M term loan, both maturing June 2027

RESMED INC

Revolver reduced from $1.6B to $1.5B; includes uncommitted $1B increase option.
New $200M term loan from ResMed Pty subsidiary; amortizes $5M semi-annually.
Both facilities mature June 29, 2027; interest at SOFR+0.75%-1.50% or Base Rate+0.0%-0.50%.
Proceeds for general corporate purposes; financial covenant maintains max leverage ratio.
Obligations guaranteed by specified U.S. subsidiaries including Brightree and MatrixCare.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.